Valuable insight into the anticancer activity of the platinum-histone deacetylase inhibitor conjugate, cis-[Pt(NH3)2malSAHA -2H)]

Molecular Pharmaceutics

Volumn 9, Issue 7, 2012, Pages 1990-1999

  Brabec, Viktor ^a   Griffith, Darren M ^b   Kisova, Anna ^a   Kostrhunova, Hana ^a   Zerzankova, Lenka ^a   Marmion, Celine J ^b   Kasparkova, Jana ^a  

^a INSTITUTE OF BIOPHYSICS   (Czech Republic)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

cellular accumulation; cisplatin; cytotoxicity; DNA binding; histone deacetylase inhibitor; SAHA

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; GLUTATHIONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MALONIC ACID; THIOUREA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ADHESION; CELL CYCLE; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; CYTOPLASM; CYTOSOL; CYTOTOXICITY; DNA BINDING; DNA REPLICATION; DNA SYNTHESIS; DNA TRANSCRIPTION; DRUG DEVELOPMENT; DRUG EFFECT; DRUG POTENCY; ENZYME INHIBITION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DNA; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; ORGANOPLATINUM COMPOUNDS;

EID: 84863309925     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp300038f     Document Type: Article

References (50)

1. Kelland, L. The resurgence of platinum-based cancer chemotherapy Nat. Rev. Cancer 2007, 7, 573-584
2. Lokich, J. What is the "best" platinum: Cisplatin, carboplatin, or oxaliplatin? Cancer Invest. 2001, 19, 756-760
3. Alderden, R. A.; Hall, M. D.; Hambley, T. W. The discovery and development of cisplatin J. Chem. Educ. 2006, 83, 728-734
4. Galanski, M.; Jakupec, M. A.; Keppler, B. K. Update of the preclinical situation of anticancer platinum complexes: Novel design strategies and innovative analytical approaches Curr. Med. Chem. 2005, 12, 2075-2094
5. Cepeda, V.; Fuertes, M.; Castilla, J.; Alonso, C.; Quevedo, C.; Perez, J. M. Biochemical mechanisms of cisplatin cytotoxicity Anti-Cancer Agents Med. Chem. 2007, 7, 3-18
6. Wang, D.; Lippard, S. J. Cellular processing of platinum anticancer drugs Nat. Rev. Drug Discovery 2005, 4, 307-320
7. Jung, Y.; Lippard, S. J. Direct cellular responses to platinum-induced DNA damage Chem. Rev. 2007, 107, 1387-1407
8. Brabec, V. DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair Prog. Nucleic Acid Res. Mol. Biol. 2002, 71, 1-68
9. Wong, E.; Giandomenico, C. M. Current status of platinum-based antitumor drugs Chem. Rev. 1999, 99, 2451-2466
10. Griffith, D.; Parker, J. P.; Marmion, C. J. Enzyme inhibition as a key target for the development of novel metal-based anti-cancer therapeutics Anti-Cancer Agents Med. Chem. 2010, 10, 354-370
11. Griffith, D.; Morgan, M. P.; Marmion, C. J. A novel anti-cancer bifunctional platinum drug candidate with dual DNA binding and histone deacetylase inhibitory activity Chem. Commun. 2009, 6735-6737
12. Botrugno, O. A.; Santoro, F.; Minucci, S. Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer Cancer Lett. 2009, 280, 134-144
13. Butler, L. M.; Zhou, X.; Xu, W.-S.; Scher, H. I.; Rifkind, R. A.; Marks, P. A.; Richon, V. M. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 11700-11705
14. Xu, W. S.; Parmigiani, R. B.; Marks, P. A. Histone deacetylase inhibitors: molecular mechanisms of action Oncogene 2007, 26, 5541-5552
15. Tan, J.; Cang, S.; Ma, Y.; Petrillo, R.; Liu, D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents J. Hematol. Oncol. 2010, 3, 5-17
16. Lane, A. A.; Chabner, B. A. Histone deacetylase inhibitors in cancer therapy J. Clin. Oncol. 2009, 27, 5459-5468
17. Marks, P. A. Discovery and development of SAHA as an anticancer agent Oncogene 2007, 26, 1351-1356
18. Kelly, W. K.; Marks, P. A. Drug insight: histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid Nat. Clin. Pract. Oncol. 2005, 2, 150-157
19. Duvic, M.; Vu, J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma Expert Opin. Invest. Drugs 2007, 16, 1111-1120
20. Shabason, J. E.; Tofilon, P. J.; Camphausen, K. HDAC inhibitors in cancer care Oncol.-N.Y. 2010, 24, 180-185
21. Cang, S.; Ma, Y.; Liu, D. New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer J. Hematol. Oncol. 2009, 2, 22-32
22. Kim, M. S.; Blake, M.; Baek, J. H.; Kohlhagen, G.; Pommier, Y.; Carrier, F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA Cancer Res. 2003, 63, 7291-7300
23. Brabec, V.; Palecek, E. The influence of salts and pH on polarographic currents produced by denatured DNA Biophysik 1970, 6, 290-300
24. Brabec, V.; Palecek, E. Interaction of nucleic acids with electrically charged surfaces. II. Conformational changes in double-helical polynucleotides Biophys. Chem. 1976, 4, 76-92
25. Chavez-Blanco, A.; Segura-Pacheco, B.; Perez-Cardenas, E.; Taja-Chayeb, L.; Cetina, L.; Candelaria, M.; Cantu, D.; Gonzalez-Fierro, A.; Garcia-Lopez, P.; Zambrano, P.; Perez-Plasencia, C.; Cabrera, G.; Trejo-Becerril, C.; Angeles, E.; Duenas-Gonzalez, A. Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study Mol. Cancer 2005, 4, 3-11
26. Zhu, W.-G.; Lakshmanan, R. R.; Beal, M. D.; Otterson, G. A. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors Cancer Res. 2001, 61, 1327-1333
27. Alley, M. C.; Scudiero, D. A.; Monks, A.; Hursey, M. L.; Czerwinski, M. J.; Fine, D. L.; Abbott, B. J.; Mayo, J. G.; Shoemaker, R. H.; Boyd, M. R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay Cancer Res. 1988, 48, 589-601
28. Abassi, Y. A.; Xi, B.; Zhang, W. F.; Ye, P. F.; Kirstein, S. L.; Gaylord, M. R.; Feinstein, S. C.; Wang, X. B.; Xu, X. Kinetic cell-based morphological screening: Prediction of mechanism of compound action and off-target effects Chem. Biol. 2009, 16, 712-723
29. Harris, A. L.; Yang, X.; Hegmans, A.; Povirk, L.; Ryan, J. J.; Kelland, L.; Farrell, N. P. Synthesis, characterization, and cytotoxicity of a novel highly charged trinuclear platinum compound. Enhancement of cellular uptake with charge Inorg. Chem. 2005, 44, 9598-9600
30. Kasparkova, J.; Novakova, O.; Vrana, O.; Intini, F.; Natile, G.; Brabec, V. Molecular aspects of antitumor effects of a new platinum(IV) drug Mol. Pharmacol. 2006, 70, 1708-1719
31. Johnson, N. P.; Butour, J.-L.; Villani, G.; Wimmer, F. L.; Defais, M.; Pierson, V.; Brabec, V. Metal antitumor compounds: The mechanism of action of platinum complexes Prog. Clin. Biochem. Med. 1989, 10, 1-24
32. Jamieson, E. R.; Lippard, S. J. Structure, recognition, and processing of cisplatin-DNA adducts Chem. Rev. 1999, 99, 2467-2498
33. 195Pt NMR kinetic and mechanistic studies of cis-diamminedichloroplatinum and trans-diamminedichloroplatinum(II) binding to DNA J. Am. Chem. Soc. 1990, 112, 6860-6871
34. Cutbush, S. D.; Kuroda, R.; Neidle, S.; Robins, A. B. The antitumor complex ethylenediamine platinum(II) malonate: X-ray structure analysis and studies of its stability in solution J. Inorg. Biochem. 1983, 18, 213-220
35. Cleare, M. J.; Hydes, P. C.; Malerbi, B. W.; Watkins, D. M. Anti-tumor platinum complexes: relationship between chemical properties and activity Biochimie 1978, 60, 835-850
36. Cleare, M. J.; Hoeschele, J. D. Antitumor activity of group VIII transition metal complexes. 1. Platinum(ll) complexes Bioinorg. Chem. 1973, 2, 187-210
37. Macquet, J. P.; Butour, J. L. Modifications of the DNA secondary structure upon platinum binding: a proposed model Biochimie 1978, 60, 901-914
38. Macquet, J. P.; Butour, J. L. Platinum-amine compounds: Importance of the labile and inert ligands for their pharmacological activities toward L1210 leukemia cells J. Natl. Cancer Inst. 1983, 70, 899-905
39. Barnham, K. J.; Djuran, M. I.; Murdoch, P. d. S.; Ranford, J. D.; Sadler, P. J. Ring-opened adducts of the anticancer drug carboplatin with sulfur amino acids Inorg. Chem. 1996, 35, 1065-1072
40. Natarajan, G.; Malathi, R.; Holler, E. Increased DNA binding activity of cis-1,1-cyclobutanedicarboxylatodiammineplatinum(II) (Carboplatin) in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts: Activation theory revisited Biochem. Pharmacol. 1999, 58, 1625-1629
41. Howe-Grant, M.; Lippard, S. J. Binding of platinum(II) intercalation reagents to DNA. Dependence on base pair composition, nature of the intercalator, and ionic strength Biochemistry 1979, 18, 5762-5769
42. Tikoo, K.; Ali, I. Y.; Gupta, J.; Gupta, C. 5-Azacytidine prevents cisplatin induced nephrotoxicity and potentiates anticancer activity of cisplatin by involving inhibition of metallothionein, pAKT and DNMT1 expression in chemical induced cancer rats Toxicol. Lett. 2009, 191, 158-166
43. Koprinarova, M.; Markovska, P.; Iliev, I.; Anachkova, B.; Russev, G. Sodium butyrate enhances the cytotoxic effect of cisplatin by abrogating the cisplatin imposed cell cycle arrest BMC Mol. Biol. 2010, 11, 49-57
44. Mai, A. The therapeutic uses of chromatin-modifying agents Expert Opin. Ther. Targets 2007, 11, 835-851
45. Codd, R.; Braich, N.; Liu, J.; Soe, C. Z.; Pakchung, A. A. H. Zn(II)-dependent histone deacetylase inhibitors: Suberoylanilide hydroxamic acid and trichostatin A Int. J. Biochem. Cell Biol. 2009, 41, 736-739
46. Dokmanovic, M.; Perez, G.; Xu, W. S.; Ngo, L.; Clarke, C.; Parmigiani, R. B.; Marks, P. A. Histone deacetylase inhibitors selectively suppress expression of HDAC7 Mol. Cancer Ther. 2007, 6, 2525-2534
47. Lee, J. H.; Choy, M. L.; Ngo, L.; Foster, S. S.; Marks, P. A. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 14639-14644
48. Ozaki, K.; Kishikawa, F.; Tanaka, M.; Sakamoto, T.; Tanimura, S.; Kohno, M. Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs Cancer Sci. 2008, 99, 376-384
49. Frew, A. J.; Johnstone, R. W.; Bolden, J. E. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors Cancer Lett. 2009, 280, 125-133
50. Rasheed, W.; Bishton, M.; Johnstone, R. W.; Prince, H. M. Histone deacetylase inhibitors in lymphoma and solid malignancies Expert Rev. Anticancer Ther. 2008, 8, 413-432